TW202012391A - 二芳基醚型喹唑啉衍生物 - Google Patents

二芳基醚型喹唑啉衍生物 Download PDF

Info

Publication number
TW202012391A
TW202012391A TW108123293A TW108123293A TW202012391A TW 202012391 A TW202012391 A TW 202012391A TW 108123293 A TW108123293 A TW 108123293A TW 108123293 A TW108123293 A TW 108123293A TW 202012391 A TW202012391 A TW 202012391A
Authority
TW
Taiwan
Prior art keywords
oxy
fluoro
piperidin
prop
mmol
Prior art date
Application number
TW108123293A
Other languages
English (en)
Chinese (zh)
Inventor
吉田賢一
竹內孝輔
井上英和
影治秀晃
百瀨孝幸
吉田佳右
神保猛
江上晶子
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW202012391A publication Critical patent/TW202012391A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW108123293A 2018-07-04 2019-07-02 二芳基醚型喹唑啉衍生物 TW202012391A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-127829 2018-07-04
JP2018127829 2018-07-04

Publications (1)

Publication Number Publication Date
TW202012391A true TW202012391A (zh) 2020-04-01

Family

ID=69059535

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108123293A TW202012391A (zh) 2018-07-04 2019-07-02 二芳基醚型喹唑啉衍生物

Country Status (15)

Country Link
US (1) US20230025510A1 (https=)
EP (1) EP3822263A4 (https=)
JP (1) JP7288904B2 (https=)
KR (1) KR20210029165A (https=)
CN (1) CN112334460A (https=)
AU (1) AU2019297889A1 (https=)
BR (1) BR112020027064A2 (https=)
CA (1) CA3105602A1 (https=)
CO (1) CO2021000800A2 (https=)
IL (1) IL279858A (https=)
MX (1) MX2021000014A (https=)
PH (1) PH12021550003A1 (https=)
SG (1) SG11202013218QA (https=)
TW (1) TW202012391A (https=)
WO (1) WO2020009156A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896726B (zh) * 2020-08-10 2025-09-11 大陸商上海和譽生物醫藥科技有限公司 一種ｅｇｆｒ抑制劑及其製備方法和應用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
CN113264888A (zh) * 2021-03-04 2021-08-17 江苏康可得生物技术股份有限公司 酪氨酸激酶抑制剂及其药物应用
KR20230156767A (ko) * 2021-03-19 2023-11-14 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 퀴나졸린계 화합물, 조성물 및 퀴나졸린계 화합물의 적용
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
US20250136595A1 (en) * 2022-02-09 2025-05-01 Enliven Inc. Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
TW202404590A (zh) * 2022-04-05 2024-02-01 美商纜圖藥品公司 Ｅｇｆｒ抑制劑
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2025167927A1 (zh) * 2024-02-05 2025-08-14 苏州韬略生物科技股份有限公司 三取代喹唑啉衍生物及其酸加成盐及其药物组合物和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228446B1 (en) * 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
CA2527017A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2013173254A1 (en) * 2012-05-14 2013-11-21 Dawei Zhang Bicyclic compounds as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
MA46852A (fr) 2016-11-17 2019-09-25 Univ Texas Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20
WO2020262998A1 (ko) * 2019-06-26 2020-12-30 한미약품 주식회사 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896726B (zh) * 2020-08-10 2025-09-11 大陸商上海和譽生物醫藥科技有限公司 一種ｅｇｆｒ抑制劑及其製備方法和應用

Also Published As

Publication number Publication date
PH12021550003A1 (en) 2021-09-20
IL279858A (en) 2021-03-01
AU2019297889A1 (en) 2021-02-18
EP3822263A1 (en) 2021-05-19
CA3105602A1 (en) 2020-01-09
JPWO2020009156A1 (ja) 2021-07-15
KR20210029165A (ko) 2021-03-15
MX2021000014A (es) 2021-03-09
CO2021000800A2 (es) 2021-02-08
WO2020009156A1 (ja) 2020-01-09
EP3822263A4 (en) 2022-03-16
SG11202013218QA (en) 2021-02-25
CN112334460A (zh) 2021-02-05
US20230025510A1 (en) 2023-01-26
JP7288904B2 (ja) 2023-06-08
BR112020027064A2 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TW202012391A (zh) 二芳基醚型喹唑啉衍生物
CN114026073B (zh) 用于治疗braf相关的疾病和障碍的喹唑啉-4-酮衍生物
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
EP3896062A1 (en) Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
US12077519B2 (en) Heteroaryl carboxamide compound
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
JP2022078109A (ja) 核輸送モジュレーターとしての化合物およびその使用
EP1559715B1 (en) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
JP6433505B2 (ja) オレキシン受容体アンタゴニストとしての１，２−置換シクロペンタン
CN108026102A (zh) 可用于治疗与kit和pdgfr相关的病症的化合物
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
EP3985000A1 (en) 2,4-disubstituted pyrimidine derivative, preparation method for same, and uses thereof
JP2018520205A (ja) レンバチニブメシル酸塩の新規結晶形及びその製造方法
EP3590941B1 (en) Urea-substituted aromatic ring-linked dioxane-quinazoline and -linked dioxane-quinoline compounds, preparation method therefor and use thereof
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
JP7840327B2 (ja) 新規インダゾールアセチレン誘導体
EP2303276B1 (en) Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
US9884856B2 (en) Crystal form of Dabrafenib mesylate and preparation method thereof
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
CN108368094B (zh) 用于局部药物递送的非甾体类糖皮质激素受体调节剂
JP5748745B2 (ja) ｐ７０Ｓ６キナーゼの阻害剤としての置換ベンゾトリアジン類およびキノキサリン類
TW202012414A (zh) 三環ask1抑制劑
HK40043221A (en) Biaryl ether-type quinazoline derivative
CN111620821A (zh) 取代的吡唑类化合物及包含该化合物的组合物及其用途
TW202110844A (zh) 具有二螺二酮哌構造之化合物